Karl J. Puttlitz

Array ( [id] => 20099030 [patent_doc_number] => 20250228966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-17 [patent_title] => LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 19/171920 [patent_app_country] => US [patent_app_date] => 2025-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19171920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20308064 [patent_doc_number] => 20250325693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-23 [patent_title] => ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING [patent_app_type] => utility [patent_app_number] => 19/097573 [patent_app_country] => US [patent_app_date] => 2025-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19097573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20178351 [patent_doc_number] => 20250262309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS [patent_app_type] => utility [patent_app_number] => 19/078822 [patent_app_country] => US [patent_app_date] => 2025-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19078822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20192342 [patent_doc_number] => 20250269052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => ANTI-CEACAM5 ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 19/064273 [patent_app_country] => US [patent_app_date] => 2025-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46745 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19064273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19890367 [patent_doc_number] => 20250115679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/957324 [patent_app_country] => US [patent_app_date] => 2024-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18957324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19984084 [patent_doc_number] => 20250122306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/914023 [patent_app_country] => US [patent_app_date] => 2024-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18914023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20239660 [patent_doc_number] => 12419964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload [patent_app_type] => utility [patent_app_number] => 18/904628 [patent_app_country] => US [patent_app_date] => 2024-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 15223 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18904628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19982863 [patent_doc_number] => 20250121085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 45 SKIPPING [patent_app_type] => utility [patent_app_number] => 18/903935 [patent_app_country] => US [patent_app_date] => 2024-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40976 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18903935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19722816 [patent_doc_number] => 20250025567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND [patent_app_type] => utility [patent_app_number] => 18/896098 [patent_app_country] => US [patent_app_date] => 2024-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 273 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18896098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19641455 [patent_doc_number] => 20240415975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAME [patent_app_type] => utility [patent_app_number] => 18/802353 [patent_app_country] => US [patent_app_date] => 2024-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18802353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613280 [patent_doc_number] => 20240398960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/787110 [patent_app_country] => US [patent_app_date] => 2024-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18787110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496535 [patent_doc_number] => 20240335553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => Fc GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 18/753148 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613302 [patent_doc_number] => 20240398982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/731223 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18731223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19700107 [patent_doc_number] => 12194106 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Antibodies targeting LIV-1 and uses thereof [patent_app_type] => utility [patent_app_number] => 18/656166 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23447 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18656166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432547 [patent_doc_number] => 20240301045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => ANTIBODY AGAINST ADVANCED GLYCATION END PRODUCTS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/648976 [patent_app_country] => US [patent_app_date] => 2024-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18648976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19799028 [patent_doc_number] => 20250064953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => Antibody, Linkers, Payload, Conjugates and Applications Thereof [patent_app_type] => utility [patent_app_number] => 18/620025 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18620025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19563564 [patent_doc_number] => 12138315 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Anti-CD37 antibody-drug conjugate [patent_app_type] => utility [patent_app_number] => 18/411436 [patent_app_country] => US [patent_app_date] => 2024-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 16 [patent_no_of_words] => 25542 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18411436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793332 [patent_doc_number] => 12234262 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-25 [patent_title] => Vaccinia virus recombinant A33R protein and kit for diagnosing antibodies against orthopoxvirus comprising the same [patent_app_type] => utility [patent_app_number] => 18/393436 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10183 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441452 [patent_doc_number] => 12091694 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Fc fusion molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 18/512556 [patent_app_country] => US [patent_app_date] => 2023-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 160010 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19563565 [patent_doc_number] => 12138316 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Anti-B7H3 antibody-drug conjugate and use thereof [patent_app_type] => utility [patent_app_number] => 18/511591 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 29 [patent_no_of_words] => 33400 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511591 [rel_patent_id] =>[rel_patent_doc_number] =>)